These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 28108196)
1. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196 [TBL] [Abstract][Full Text] [Related]
2. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. Cheng FC; Kuo JS; Chia LG; Dryhurst G J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186 [TBL] [Abstract][Full Text] [Related]
4. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059 [TBL] [Abstract][Full Text] [Related]
5. Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Lunardi G; Galati S; Tropepi D; Moschella V; Brusa L; Pierantozzi M; Stefani A; Rossi S; Fornai F; Fedele E; Stanzione P; Hainsworth AH; Pisani A Parkinsonism Relat Disord; 2009 Jun; 15(5):383-9. PubMed ID: 19010710 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875 [TBL] [Abstract][Full Text] [Related]
7. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. LeWitt PA; Galloway MP; Matson W; Milbury P; McDermott M; Srivastava DK; Oakes D Neurology; 1992 Nov; 42(11):2111-7. PubMed ID: 1436520 [TBL] [Abstract][Full Text] [Related]
8. Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid. Loeffler DA; LeWitt PA; DeMaggio AJ; Juneau PL; Milbury PE; Matson WR J Neural Transm Park Dis Dement Sect; 1995; 9(1):45-53. PubMed ID: 7605589 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. Kremer T; Taylor KI; Siebourg-Polster J; Gerken T; Staempfli A; Czech C; Dukart J; Galasko D; Foroud T; Chahine LM; Coffey CS; Simuni T; Weintraub D; Seibyl J; Poston KL; Toga AW; Tanner CM; Marek K; Hutten SJ; Dziadek S; Trenkwalder C; Pagano G; Mollenhauer B Mov Disord; 2021 Aug; 36(8):1972-1978. PubMed ID: 33942926 [TBL] [Abstract][Full Text] [Related]
10. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
11. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. LeWitt P; Schultz L; Auinger P; Lu M; Brain Res; 2011 Aug; 1408():88-97. PubMed ID: 21784416 [TBL] [Abstract][Full Text] [Related]
12. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163 [TBL] [Abstract][Full Text] [Related]
13. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Poceta JS; Parsons L; Engelland S; Kripke DF Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455 [TBL] [Abstract][Full Text] [Related]
14. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa. Durso R; Evans JE; Josephs E; Szabo GK; Evans BA; Handler JS; Jennings D; Browne TR Ann Neurol; 1997 Sep; 42(3):300-4. PubMed ID: 9307250 [TBL] [Abstract][Full Text] [Related]
15. Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography. Watson E; Wilk S Psychopharmacologia; 1975 Apr; 42(1):57-6. PubMed ID: 1153623 [TBL] [Abstract][Full Text] [Related]
16. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid. Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587 [TBL] [Abstract][Full Text] [Related]
17. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment]. Liu DK Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746 [TBL] [Abstract][Full Text] [Related]
19. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat. Mignot E; Laude D; Elghozi JL J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472 [TBL] [Abstract][Full Text] [Related]
20. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa. Extein I; Van Woert M; Roth RH; Bowers MB Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]